Medpace - MEDP Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View MEDP analyst ratings or view top-rated stocks.

3 brokerages have issued 12-month target prices for Medpace's shares. Their MEDP share price forecasts range from $233.00 to $238.00. On average, they anticipate the company's share price to reach $235.50 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price.
View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts.

Medpace's stock was trading at $212.41 at the beginning of 2023. Since then, MEDP stock has decreased by 13.3% and is now trading at $184.13.
View the best growth stocks for 2023 here.

Medpace saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,490,000 shares, an increase of 23.1% from the February 28th total of 1,210,000 shares. Based on an average daily volume of 318,100 shares, the short-interest ratio is currently 4.7 days. Approximately 6.3% of the shares of the stock are sold short.
View Medpace's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, April 24th 2023.
View our MEDP earnings forecast.

Medpace will be holding an earnings conference call on Tuesday, April 25th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its earnings results on Monday, February, 13th. The company reported $2.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.78 by $0.34. The business earned $394.10 million during the quarter, compared to the consensus estimate of $386.09 million. Medpace had a net margin of 16.81% and a trailing twelve-month return on equity of 60.42%. The business's revenue was up 27.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.32 earnings per share.

ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), Franklin Genomic Advancements ETF (HELX), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Argent Mid Cap ETF (AMID), WisdomTree U.S. Growth & Momentum Fund (WGRO), Global X Founder-Run Companies ETF (BOSS) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

Medpace issued an update on its FY 2023 earnings guidance on Tuesday, February, 14th. The company provided EPS guidance of $7.53-$8.14 for the period, compared to the consensus estimate of $7.72. The company issued revenue guidance of $1.69 billion-$1.75 billion, compared to the consensus revenue estimate of $1.70 billion.

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Fuller & Thaler Asset Management Inc. (3.02%), Dimensional Fund Advisors LP (1.90%), Geode Capital Management LLC (1.88%), Boston Trust Walden Corp (1.76%), Riverbridge Partners LLC (1.47%) and Millennium Management LLC (1.45%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends.

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEDP stock can currently be purchased for approximately $184.13.

Medpace (NASDAQ:MEDP) has a market capitalization of $5.72 billion and generates $1.46 billion in revenue each year. The company earns $245.37 million in net income (profit) each year or $7.32 on an earnings per share basis.

The company employs 5,200 workers across the globe.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444.